Enterococcus durans as Next Generation Probiotics

Next-generation probiotics (NGPs) discovery is an innovative area of research that plays a critical role in the treatment of many diseases, especially for cancers. With breaking edge tools and state-of-art technologies, Creative Biolabs provides a series of novel Enterococcus durans (E. durans)-based services targeting different kinds of human and animal disease types. Our unique and innovative solutions for the discovery and development of E. durans-based NGPs have won a great reputation in our worldwide customers. We are dedicated to helping you succeed by providing high-quality services and support to translate your ideal from early research to clinical trials.

Introduction to E. durans

E. durans is a gram-positive facultative anaerobe that can be commonly found in the human and animal intestines. E. durans is essential to cheese ripening and aroma development of the food industry. Moreover, pilot studies have illustrated that some E. durans strain could be the main cause of various infectious diseases in humans. The antibiotic resistance genes of E. durans strain may be key factors for toxicity and pathogenicity in human infections. As a result, the isolation of E. durans strains from food and human samples for clinically relevant antibiotics have aroused much attention in disease therapy. However, recent studies have suggested that several E. durans strains have long been a priority in animals as novel NGPs. Besides, as safety concerns continue to be updated, the clinical use of more E. durans strains in humans can be also envisaged.

Fig.1 Hemolysin activity of Enterococcus durans KLDS6.0930 strain. (Li, 2018)

E. durans for Disease Treatment

E. durans, a rare member of enterococcal species, is one of the common species used as probiotic in disease prevention and treatment. As a reliable CRO company, Creative Biolabs is committed and proud to be part of this rewarding challenge by offering its support to the pre-clinical and commercial manufacture of your E. durans-based NGP candidates. We are proud to partner with our clients on the journey of bringing novel E. durans-based live biotherapeutics drugs to different disease therapy applications, including but not limited to:

Gastrointestinal Disorders

The gastrointestinal disorders are a series of functional and motility diseases that often occur in the gastrointestinal tract. Up to now, many types of gastrointestinal disorders, such as Celiac disease, Constipation, inflammatory bowel disease (IBD), and ulcerative colitis (UC), have been identified and widely studied. E. durans-based NGP strategies for the prevention or treatment use against various gastrointestinal disorders have become more and more popular. For instance, E. durans EP1 strain can increase the sIgA level in feces and possess strong anti-inflammatory effects in IBD mice.

Urinary Tract Disorders

Urinary tract disorders are a group of diseases in the urinary system, including kidneys, ureters, bladder, as well as urethra. Symptoms of a urinary tract disorder depend on the specific part of the urinary system, but they can be serious or even life-threatening. Nowadays, some E. durans strains have been shown therapeutic and prophylactic properties, such as immune system regulation and antimicrobial activity, in multiple urinary disease models. In a recent study, E. durans KLDS6.0930 strain has been isolated and identified its NGP potential in mice models. Furthermore, the safety of the KLDS6.0930 strain has also been systematically evaluated by using whole-genome sequencing. The results have revealed that the KLDS6.0930 strain is safe and effective for treating human urinary tract disorders.

Creative Biolabs is a leading CRO company that is dedicated to helping our worldwide customers shorten the discovery and development time in live biotherapeutics drugs. We are also specialized in improving current approaches of E. durans-based studies, which can boost long term efficacy and reduce the cost to a more affordable level. Please feel free to contact us to get more information and a quote for any E. durans-based therapy module.

Reference

Li, B., et al. Evaluating the safety of potential probiotic Enterococcus durans KLDS6. 0930 using whole-genome sequencing and oral toxicity study. Frontiers in microbiology. 2018, 9: 1943.

CAT	Product Name	Product Overview
LBST-112FG	Enterococcus durans; 4ADU-4	Enterococcus durans is a microaerophile, mesophilic bacterium that was isolated from excrement of weaned piglets.
LBST-113FG	Enterococcus durans; St	Enterococcus durans is a microaerophile, mesophilic bacterium that was isolated from Yoghurt.